EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial

Hung-Kuan Yen, Chia-Che Lee, Chen-Yu Wang, Ta-Chun Lin, Shau-Huai Fu, Chuan-Ching Huang, Chih-Chien Hung, Olivier Q Groot, Chung-Yi Li iD

Clinical Pharmacology & Therapeutics · 2026-02 · 119 (2) · 480-489

DOI: 10.1002/cpt.70088 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 07.10.2025. Verfasst von Hung-Kuan Yen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, National Taiwan University Hospital, Taipei City, Taiwan. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Zoledronic Acid, Bone Density. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

After denosumab discontinuation, the rebound effect can lead to rapid bone loss and increased fracture risk. Identifying effective sequential therapies after denosumab discontinuation is crucial to mitigate these risks. We conducted the Denosumab Sequential Therapy (DST) trial, a two‐year, multicenter, open‐label, randomized controlled trial, conducted at a referral center and two affiliated hospitals in Taiwan. The DST trial enrolled 101 patients aged 50 years or older who received denosumab for at least 2 years (median: 2 years) and stratified the patients into four intervention groups to evaluate the effectiveness of three therapeutic strategies compared to continuous denosumab treatment. The four arms were as follows: (1) continued denosumab for 2 years (denosumab group); (2) two consecutive annual zoledronate infusions (annual‐zoledronate group); (3) one zoledronate infusion followed by a supervised medication‐free year (biennial‐zoledronate group); and (4) one zoledronate infusion followed by resumed denosumab (double‐switching group). The primary outcome was the percent change in the lumbar spine (LS) bone mineral density (BMD), total hip BMD (TH‐BMD), and femoral neck BMD (FN‐BMD). Secondary outcomes included changes in BTMs, the incidence of clinical fractures, and the need for rescue zoledronate in the biennial‐zoledronate group. LS‐BMD increased by 1.77% in the denosumab group, by 2.25% in the double‐switching group, while decreasing by 0.71% in the annual‐zoledronate group and by 2.76% in the biennial‐zoledronate group. One‐third of patients in the biennial‐zoledronate group showed LS‐BMD loss exceeding the least significant change (LSC), and 22% required rescue zoledronate infusions. Given the significant bone loss observed, a single zoledronate infusion followed by a medication‐free year is not recommended. Two consecutive zoledronate infusions and the double‐switching regimen with resumed denosumab showed promising BMD preservation, making them advisable clinical alternatives after denosumab discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBone Density Conservation AgentsZoledronic AcidBone DensityHumansFemaleMiddle AgedAgedMaleDrug Administration ScheduleTaiwanTreatment Outcome

Substanzen

DenosumabBone Density Conservation AgentsZoledronic Acid

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, National Taiwan University Hospital, Taipei City, Taiwan.
  • Department of Medical Education, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu City, Taiwan.
  • Department of Orthopaedic Surgery, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu City, Taiwan.
  • Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei City, Taiwan.
  • Department of Pharmacy, National Taiwan University Hospital Yun-Lin Branch, Douliu City, Yunlin County, Taiwan.
  • National Center for Geriatrics and Welfare Research, National Health Research Institutes, Huwei Township, Yunlin County, Taiwan.

ORCID-Profile: Chung-Yi Li

Zitieren

APA

Yen, H. K., Lee, C. C., Wang, C. Y., Lin, T. C., Fu, S. H., Huang, C. C., Hung, C. C., Groot, O. Q., & Li, C. Y. (2026). Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial. Clinical Pharmacology & Therapeutics, 119(2), 480-489. https://doi.org/10.1002/cpt.70088

Vancouver

Yen HK, Lee CC, Wang CY, Lin TC, Fu SH, Huang CC, et al. Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial. Clinical Pharmacology & Therapeutics. 2026;119(2):480-489. doi:10.1002/cpt.70088

BibTeX
@article{Yen2026,
  author = {Yen, Hung-Kuan and Lee, Chia-Che and Wang, Chen-Yu and Lin, Ta-Chun and Fu, Shau-Huai and Huang, Chuan-Ching and Hung, Chih-Chien and Groot, Olivier Q and Li, Chung-Yi},
  title = {Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {2},
  pages = {480--489},
  doi = {10.1002/cpt.70088}
}
Kostenlos starten →